


## Claims

## 1. Benzimidazolyl derivatives of formula I



wherein

10

Ar<sup>1</sup> is selected from aromatic hydrocarbons containing 6 to 14 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 10 carbon atoms and one or two heteroatoms, independently selected from N, O and S,

15

E is (CR<sup>5</sup>R<sup>6</sup>)<sub>n</sub>, wherein n is 1 or 2,

D is (CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>, wherein k is 0 or 1,

20

R<sup>5</sup>, R<sup>6</sup> are in each case independently from one another selected from H and A;

25

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are independently selected from a group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH<sub>2</sub>Hal, CH(Hal)<sub>2</sub>, C(Hal)<sub>3</sub>, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>CN, OHet, N(R<sup>11</sup>)Het, NR<sup>11</sup>COR<sup>13</sup>, NR<sup>11</sup>COOR<sup>13</sup>, CONR<sup>11</sup>R<sup>12</sup>, COOR<sup>13</sup>, (CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>Het, O(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>Het, N(R<sup>11</sup>)(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>Het, (CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>OR<sup>13</sup>, O(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, O(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>R<sup>13</sup>, NR<sup>11</sup>(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>R<sup>13</sup>, O(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>OR<sup>13</sup>, NR<sup>11</sup>(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>OR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>(CH<sub>2</sub>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>k</sub>OR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>(CH<sub>2</sub>)<sub>k</sub>OR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>COOR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>COR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>CONR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>COR<sup>13</sup>,

30

$(\text{CH}_2)_n\text{NR}^{11}\text{CONR}^{11}\text{R}^{12}$ ,  $(\text{CH}_2)_n\text{NR}^{11}\text{SO}_2\text{A}$ ,  $(\text{CH}_2)_n\text{SO}_2\text{NR}^{11}\text{R}^{12}$ ,  
 $(\text{CH}_2)_n\text{S}(\text{O})_u\text{R}^{13}$ ,  $(\text{CH}_2)_n\text{OC}(\text{O})\text{R}^{13}$ ,  $(\text{CH}_2)_n\text{COR}^{13}$ ,  $(\text{CH}_2)_n\text{SR}^{11}$ ,  
 $\text{CH}=\text{N}-\text{OA}$ ,  $\text{CH}_2\text{CH}=\text{N}-\text{OA}$ ,  $(\text{CH}_2)_n\text{NHOA}$ ,  $(\text{CH}_2)_n\text{CH}=\text{N}-\text{R}^{11}$ ,  
 $(\text{CH}_2)_n\text{OC}(\text{O})\text{NR}^{11}\text{R}^{12}$ ,  $(\text{CH}_2)_n\text{NR}^{11}\text{COOR}^{13}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OR}^{13}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{12}$ ,  $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{C}(\text{R}^{13})\text{HCOOR}^{11}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{N}(\text{R}^{12})\text{CH}_2\text{COOR}^{11}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{R}^{11})\text{CH}_2\text{CH}_2\text{NR}^{11}\text{R}^{12}$ ,  $\text{CH}=\text{CHCOOR}^{13}$ ,  
 $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$ ,  $\text{CH}=\text{CHCH}_2\text{NR}^{11}\text{R}^{12}$ ,  $\text{CH}=\text{CHCH}_2\text{OR}^{13}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{COOR}^{13})\text{COOR}^{14}$ ,  $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{COOR}^{13}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{CONH}_2)\text{CONH}_2$ ,  $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{COOR}^{13})\text{COOR}^{14}$ ,  
 $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{COOR}^{13}$ ,  $(\text{CH}_2)_n\text{N}(\text{CH}_2\text{CONH}_2)\text{CONH}_2$ ,  
 $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{14}$ ,  $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{14}$ ,  $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$ ,  
 $(\text{CH}_2)_n\text{OCN}$  and  $(\text{CH}_2)_n\text{NCO}$ , wherein

15

$\text{R}^{11}$ ,  $\text{R}^{12}$  are independently selected from a group consisting of H,  
 A,  $(\text{CH}_2)_m\text{Ar}^3$  and  $(\text{CH}_2)_m\text{Het}$ , or in  $\text{NR}^{11}\text{R}^{12}$ ,

20

$\text{R}^{11}$  and  $\text{R}^{12}$  form, together with the N-atom they are bound to, a 5-, 6-  
 or 7- membered heterocyclus which optionally contains 1 or 2  
 additional hetero atoms, selected from N, O and S,

25

$\text{R}^{13}$ ,  $\text{R}^{14}$  are independently selected from a group consisting of H,  
 Hal, A,  $(\text{CH}_2)_m\text{Ar}^4$  and  $(\text{CH}_2)_m\text{Het}$ ,

30

A is selected from the group consisting of alkyl, alkenyl, cycloalkyl,  
 alkylenecycloalkyl, alkoxy, alkoxyalkyl and saturated heterocyclyl,  
 preferably from the group consisting of alkyl, alkenyl, cycloalkyl,  
 alkylenecycloalkyl, alkoxy and alkoxyalkyl,

$\text{Ar}^3$ ,  $\text{Ar}^4$  are independently from one another aromatic hydrocarbon  
 residues comprising 5 to 12 and preferably 5 to 10 carbon atoms

which are optionally substituted by one or more substituents, selected from a group consisting of A, Hal, NO<sub>2</sub>, CN, OR<sup>15</sup>, NR<sup>15</sup>R<sup>16</sup>, COOR<sup>15</sup>, CONR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>COR<sup>16</sup>, NR<sup>15</sup>CONR<sup>15</sup>R<sup>16</sup>, NR<sup>16</sup>SO<sub>2</sub>A, COR<sup>15</sup>, SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, S(O)<sub>u</sub>A and OOCR<sup>15</sup>,

5

Het is a saturated, unsaturated or aromatic heterocyclic residue which is optionally substituted by one or more substituents, selected from a group consisting of A, Hal, NO<sub>2</sub>, CN, OR<sup>15</sup>, NR<sup>15</sup>R<sup>16</sup>, COOR<sup>15</sup>, CONR<sup>15</sup>R<sup>16</sup>, NR<sup>15</sup>COR<sup>16</sup>, NR<sup>15</sup>CONR<sup>15</sup>R<sup>16</sup>, NR<sup>16</sup>SO<sub>2</sub>A, COR<sup>15</sup>, SO<sub>2</sub>NR<sup>15</sup>R<sup>16</sup>, S(O)<sub>u</sub>A and OOCR<sup>15</sup>,

10

R<sup>15</sup>, R<sup>16</sup> are independently selected from a group consisting of H, A, and (CH<sub>2</sub>)<sub>m</sub>Ar<sup>6</sup>, wherein

15

Ar<sup>6</sup> is a 5- or 6-membered aromatic hydrocarbon which is optionally substituted by one or more substituents selected from a group consisting of methyl, ethyl, propyl, 2-propyl, tert.-butyl, Hal, CN, OH, NH<sub>2</sub> and CF<sub>3</sub>,

20

k, n and m are independently of one another 0, 1, 2, 3, 4, or 5,

Y is selected from O, S, NR<sup>21</sup>, C(R<sup>22</sup>)-NO<sub>2</sub>, C(R<sup>22</sup>)-CN and C(CN)<sub>2</sub>, wherein

25

R<sup>21</sup> is independently selected from the meanings given for R<sup>13</sup>, R<sup>14</sup> and

R<sup>22</sup> is independently selected from the meanings given for R<sup>11</sup>, R<sup>12</sup>,

30

p is independently in each case 0, 1, 2, 3, 4 or 5,

q is 0, 1, 2, 3 or 4, preferably 0, 1 or 2,

u is 0, 1, 2 or 3, preferably 0, 1 or 2,

and

5

Hal is independently selected from a group consisting of F, Cl, Br and I;

10

the tautomeric forms thereof; and the pharmaceutically acceptable derivatives, salts and solvates thereof.

2. Benzimidazolyl derivatives according to claim 1,

wherein

15

Ar<sup>1</sup> is selected from aromatic hydrocarbons containing 6 to 10 and especially 6 carbon atoms and ethylenical unsaturated or aromatic heterocyclic residues containing 3 to 8 and especially 4 to 6 carbon atoms and one or two heteroatoms, independently selected from N, O and S and especially selected from N and O,

20

R<sup>8</sup>, R<sup>9</sup> and R<sup>10</sup> are independently selected from a group consisting of H, A, cycloalkyl comprising 3 to 7 carbon atoms, Hal, CH<sub>2</sub>Hal, CH(Hal)<sub>2</sub>, C(Hal)<sub>3</sub>, NO<sub>2</sub>, (CH<sub>2</sub>)<sub>n</sub>CN, OHet, N(R<sup>11</sup>)Het, NR<sup>11</sup>COR<sup>13</sup>, NR<sup>11</sup>COOR<sup>13</sup>, CONR<sup>11</sup>R<sup>12</sup>, COOR<sup>13</sup>, (CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>Het, O(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>Het, N(R<sup>11</sup>)(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>Het, (CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>OR<sup>13</sup>, O(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, NR<sup>11</sup>(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, O(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>R<sup>13</sup>, NR<sup>11</sup>(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>R<sup>13</sup>, O(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>OR<sup>13</sup>, NR<sup>11</sup>(CR<sup>5</sup>R<sup>6</sup>)<sub>k</sub>OR<sup>13</sup>, and/or are independently selected from a group consisting of NR<sup>11</sup>COR<sup>13</sup>, NR<sup>11</sup>COOR<sup>13</sup>, CONR<sup>11</sup>R<sup>12</sup>, COOR<sup>13</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>(CH<sub>2</sub>)<sub>k</sub>NR<sup>11</sup>R<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>O(CH<sub>2</sub>)<sub>k</sub>OR<sup>11</sup>, (CH<sub>2</sub>)<sub>n</sub>NR<sup>11</sup>(CH<sub>2</sub>)<sub>k</sub>OR<sup>12</sup>, (CH<sub>2</sub>)<sub>n</sub>COR<sup>13</sup>,

25



30

$(\text{CH}_2)_n\text{COOR}^{13}$ ,  $(\text{CH}_2)_n\text{CONR}^{11}\text{R}^{12}$ ,  $(\text{CH}_2)_n\text{NR}^{11}\text{COR}^{13}$ ,  
 $(\text{CH}_2)_n\text{NR}^{11}\text{CONR}^{11}\text{R}^{12}$ ,  $(\text{CH}_2)_n\text{NR}^{11}\text{SO}_2\text{A}$ ,  $(\text{CH}_2)_n\text{SO}_2\text{NR}^{11}\text{R}^{12}$ ,  
 $(\text{CH}_2)_n\text{S(O)}_u\text{R}^{13}$ ,  $(\text{CH}_2)_n\text{OC(O)}\text{R}^{13}$ ,  $(\text{CH}_2)_n\text{COR}^{13}$ ,  $(\text{CH}_2)_n\text{SR}^{11}$ ,  
 $(\text{CH}_2)_n\text{NHOA}$ ,  $(\text{CH}_2)_n\text{NR}^{11}\text{COOR}^{13}$ ,  $(\text{CH}_2)_n\text{N(R}^{11})\text{CH}_2\text{CH}_2\text{OR}^{13}$ ,  
 $(\text{CH}_2)_n\text{N(R}^{11})\text{CH}_2\text{CH}_2\text{OCF}_3$ ,  $(\text{CH}_2)_n\text{N(R}^{11})\text{C(R}^{13})\text{HCOOR}^{12}$ ,  
 $(\text{CH}_2)_n\text{N(R}^{11})\text{C(R}^{13})\text{HCOR}^{11}$ ,  $(\text{CH}_2)_n\text{N(COOR}^{13})\text{COOR}^{14}$ ,  
 $(\text{CH}_2)_n\text{N(CONH}_2\text{)COOR}^{13}$ ,  $(\text{CH}_2)_n\text{N(CONH}_2\text{)CONH}_2$ ,  
 $(\text{CH}_2)_n\text{N(CH}_2\text{COOR}^{13})\text{COOR}^{14}$ ,  $(\text{CH}_2)_n\text{N(CH}_2\text{CONH}_2\text{)COOR}^{13}$ ,  
 $(\text{CH}_2)_n\text{N(CH}_2\text{CONH}_2\text{)CONH}_2$ ,  $(\text{CH}_2)_n\text{CHR}^{13}\text{COR}^{14}$ ,  
 $(\text{CH}_2)_n\text{CHR}^{13}\text{COOR}^{14}$  and  $(\text{CH}_2)_n\text{CHR}^{13}\text{CH}_2\text{OR}^{14}$ ,


p is 1, 2, 3 or 4, preferably 1, 2 or 3,

the tautomeric forms thereof; and the pharmaceutically acceptable derivatives, solvates, salts and stereoisomers thereof

3. Benzimidazolyl derivative according to claim 1 or 2, selected from the compounds of formula Ia, Ib, Ic, Id, Ie, If, Ig, Ih, Ii, Ij, Ik, IL, Im, In, Io, Ip, Iq and Ir,




145




1c

5




1d

10




1e

15




1f

20



1g


25



1h


30

146




ii

5




lj

10




lk

15




ll

20



lm


25



ln


30

147




Io

5




Ip

10



Iq

15



Ir,

20

wherein  $R^8$ ,  $R^9$ ,  $R^{10}$ ,  $Y$ ,  $p$  and  $q$  are as defined in claim 1 or 2,  $R^{10}$  is H or as defined in claim 1 or 2; the tautomeric forms thereof; and the pharmaceutically acceptable derivatives, salts and solvates thereof.

25

4. Benzimidazolyl derivative according to claim one of the claims 1 to 3, selected from

6-{2-[3-(4-Chloro-3-trifluoromethyl-phenyl)-ureido]-ethyl}-1H-benzoimidazole-2-carboxylic acid methylester,  
6-{2-[3-(Methoxy-trifluoromethyl-phenyl)-ureido]-ethyl}-1H-benzoimidazole-2-carboxylic acid methylester,

30



- 5-{2-[3-(Methoxy-trifluoromethyl-phenyl)-ureido]-ethyl}-1H-benzoimidazole-2-carboxylic acid methylamide,  
(5-{2-[3-(Methoxy-trifluoromethyl-phenyl)-ureido]-ethyl}-1H-benzoimidazol-2-yl)-carbamic acid methyl ester,  
5 N-(5-{2-[3-(Methoxy-trifluoromethyl-phenyl)-ureido]-ethyl}-1H-benzoimidazol-2-yl)-acetamide,  
5-{2-[3-(Chloro-trifluoromethyl-phenyl)-ureido]-ethyl}-1H-benzoimidazole-2-carboxylic acid methylamide,  
(5-{2-[3-(Chloro-trifluoromethyl-phenyl)-ureido]-ethyl}-1H-benzoimidazol-2-yl)-carbamic acid methyl ester,  
10 N-(5-{2-[3-(Chloro-trifluoromethyl-phenyl)-ureido]-ethyl}-1H-benzoimidazol-2-yl)-acetamide;  
1-[2-(2-Amino-1H-benzoimidazol-5-yl)-ethyl]-3-(4-chloro-3-trifluoromethyl-phenyl)-urea;  
15 N-(6-{2-[3-(4-Chloro-2-methoxy-5-methyl-phenyl)-ureido]-ethyl}-1H-benzoimidazol-2-yl)-acetamide;  
N-[6-(2-{3-[2-(Pyrrolidin-2-ylmethoxy)-5-trifluoromethyl-phenyl]-ureido}-ethyl)-1H-benzoimidazol-2-yl]-acetamide;  
N-(6-{2-[3-(3-Chloro-4-methyl-phenyl)-ureido]-ethyl}-1H-benzoimidazol-2-yl)-acetamide;  
20 N-(6-{2-[3-(5-Chloro-2-methoxy-4-methyl-phenyl)-ureido]-ethyl}-1H-benzoimidazol-2-yl)-acetamide;  
N-(6-{2-[3-(3-Trifluoromethyl-phenyl)-ureido]-ethyl}-1H-benzoimidazol-2-yl)-acetamide;  
25 N-(6-{2-[3-(3,4-Dichloro-phenyl)-ureido]-ethyl}-1H-benzoimidazol-2-yl)-acetamide;  
N-[6-(2-{3-[5-Methyl-2-(2-methylamino-ethoxy)-phenyl]-ureido}-ethyl)-1H-benzoimidazol-2-yl]-acetamide;  
N-[6-(2-{3-[2-(2-Methylamino-ethoxy)-5-trifluoromethyl-phenyl]-ureido}-ethyl)-1H-benzoimidazol-2-yl]-acetamide;  
30 N-[6-(2-{3-[2-(2-Amino-ethoxy)-4-chloro-5-methyl-phenyl]-ureido}-ethyl)-1H-benzoimidazol-2-yl]-acetamide;

N-[6-(2-{3-[2-(2-Amino-ethoxy)-4-chloro-5-trifluoromethyl-phenyl]-ureido}-ethyl)-1H-benzoimidazol-2-yl]-acetamide;

N-[6-(2-{3-[4-Chloro-5-methyl-2-(2-methylamino-ethoxy)-phenyl]-ureido}-ethyl)-1H-benzoimidazol-2-yl]-acetamide;

5 N-[6-(2-{3-[4-Chloro-2-(2-methylamino-ethoxy)-5-trifluoromethyl-phenyl]-ureido}-ethyl)-1H-benzoimidazol-2-yl]-acetamide;  
N-[6-(2-{3-[2-(2-Amino-ethoxy)-5-trifluoromethyl-phenyl]-ureido}-ethyl)-1H-benzoimidazol-2-yl]-acetamide;

10 the tautomeric forms thereof; and the pharmaceutically acceptable derivatives, salts and solvates thereof.


5. Benzimidazolyl derivative according to one of the claims 1 to 4 as a medicament.
- 15 6. Benzimidazolyl derivative according to one of the claims 1 to 4 as a kinase inhibitor.
7. Benzimidazolyl derivative according to claim 6, characterized in that the kinases are selected from raf-kinases, Tie-kinases, PDGFR-kinases and VEGFR-kinases.
- 20 8. Pharmaceutical composition characterised in that it contains one or more compounds according to one of the claims 1 to 4.
- 25 9. Pharmaceutical composition according to claim 8, characterised in that it contains one or more additional compounds, selected from the group consisting of physiologically acceptable excipients, auxiliaries, adjuvants, carriers and pharmaceutical active ingredients other than the compounds according to one of the claims 1 to 4.
- 30 10. Process for the manufacture of a pharmaceutical composition, characterised in that one or more compounds according to one of the

claims 1 to 4 and one or more compounds, selected from the group consisting of carriers, excipients, auxiliaries and pharmaceutical active ingredients other than the compounds according to one of the claims 1 to 4, is processed by mechanical means into a pharmaceutical composition that is suitable as dosageform for application and/or administration to a patient.

11. Use of a compound according to one of the claims 1 to 4 as a pharmaceutical.
12. Use of a compound according to one of the claims 1 to 4 in the treatment and/or prophylaxis of disorders.
13. Use of a compound according to one of the claims 1 to 4 for producing a pharmaceutical composition for the treatment and/or prophylaxis of disorders.
14. Use according to claim 12 or 13, characterised in that the disorders are caused, mediated and/or propagated by one or more kinases, selected from raf-kinases, Tie-kinases, PDGFR-kinases and VEGFR-kinases.
15. Use according to claim 12, 13 or 14, characterised in that the disorders are selected from the group consisting of hyperproliferative and nonhyperproliferative disorders.
16. Use according to claim 12, 13, 14 or 15, characterised in that the disorder is cancer.
17. Use according to claim 12, 13, 14 or 15, characterised in that the disorder is noncancerous.

- 5 18. Use according to claim 12, 13, 14, 15 or 17, characterised in that the disorders are selected from the group consisting of psoriasis, arthritis, inflammation, endometriosis, scarring, *Helicobacter pylori* infection, Influenza A, benign prostatic hyperplasia, immunological diseases, autoimmune diseases and immunodeficiency diseases.
- 10 19. Use according to one of the claims 12 to 16, characterised in that the disorders are selected from the group consisting of melanoma, brain cancer, lung cancer, squamous cell cancer, bladder cancer, gastric cancer, pancreatic cancer, hepatic cancer, renal cancer, colorectal cancer, breast cancer, head cancer, neck cancer, oesophageal cancer, gynaecological cancer, ovarian cancer, ovary cancer, uterine cancer, prostate cancer, thyroid cancer, lymphoma, chronic leukaemia and acute leukaemia.
- 15 20. Use according to one of the claims 12 to 17, characterised in that the disorders are selected from the group consisting of arthritis, restenosis; fibrotic disorders; mesangial cell proliferative disorders, diabetic nephropathy, malignant nephrosclerosis, thrombotic microangiopathy syndromes, organ transplant rejection, glomerulopathies, metabolic disorders, inflammation, solid tumors, rheumatic arthritis, diabetic retinopathy, and neurodegenerative diseases.
- 20 21. Use according to one of the claims 12 to 15, characterised in that the disorders are selected from the group consisting of rheumatoid arthritis, inflammation, autoimmune disease, chronic obstructive pulmonary disease, asthma, inflammatory bowel disease, fibrosis, atherosclerosis, restenosis, vascular disease, cardiovascular disease, inflammation, renal disease and angiogenesis disorders.
- 25 22. Use of a compound according to one of the claims 1 to 4 as a kinase inhibitor.
- 30

23. Use according to claim 22, characterised in that the kinase is one or more kinases selected from the group consisting of raf-kinases, Tie-kinases, PDGFR-kinases, VEGFR-kinases and p38-kinases.
24. Method for the treatment and/or prophylaxis of disorders, characterised in that one or more compounds according to one of the claims 1 to 4 is administered to a patient in need of such a treatment.
25. Method according to claim 24, characterised in that the one or more compounds according to one of the claims claim 1 to 4 are administered as a pharmaceutical composition according to claim 8 or 9.
26. Method for the treatment and/or prophylaxis of disorders according to claim 25, characterised in that the disorders are as defined in one of the claims 14 to 21.
27. Method for the treatment according to claim 26, characterised in that the disorder is cancerous cell growth mediated by raf-kinase, Tie kinases, PDGFR kinases and/or VEGFR kinases.
28. Method for producing compounds of formula I, characterised in that  
a) a compound of formula II,



wherein

$L^1$  and  $L^2$  either independently from one another represent a leaving group, or together represent a leaving group, and Y is as

defined above/below,

is reacted with

- 5           b) a compound of formula III



10


wherein

$L^3$  and  $L^4$  are independently from one another H or a metal ion,  
and wherein  $R^8$  and  $p$  are as defined in claim 1,

and

15

- c) a compound of formula IV,



20

wherein

$L^5$  and  $L^6$  are independently from one another H or a metal ion,


25

$FG^1$  is  $NHR^6$ ,

$FG^2$  is  $NH_2$  oder  $NO_2$ ,

and  $E$ ,  $D$ ,  $R^9$ , and  $q$  are as defined in claim 1, to obtain a  
compound of formula V


30



- 10
- d) subjecting the compound of formula V to a reduction step, if  $FG^2$  is  $NO_2$ , to transfer the  $NO_2$  group into a  $NH_2$  group, and reacting the compound of formula V, wherein  $FG^1$  is  $NHR^6$  and  $FG^2$  is  $NH_2$ , with  $Hal_3C-C(=NH)OA$  to obtain a compound of formula I, wherein  $R^{10}$  is  $CHal_3$ ; or with  $HalCN$  to obtain a compound of formula I, wherein  $R^{10}$  is  $NH_2$ ;
- 15
- e) and optionally transferring the compound obtained from step d) into a compound of formula I, wherein  $R^{10}$  is other than  $CHal_3$  or  $NH_2$ ,
- f) and optionally isolating and/or treating the compound of formula I as obtained by said reaction, with an acid, to obtain the salt thereof.
- 20


29. Method for producing compounds of formula I, characterised in that

- a) a compound of formula IIIb



wherein  $R^8$ ,  $Ar^1$ ,  $p$  and  $Y$  are as defined in claim 1, is reacted with

- 30
- b) a compound of formula IV,



IV


wherein

$L^5$  and  $L^6$  are independently from one another H or a metal ion,

$FG^1$  is  $NHR^6$ ,

$FG^2$  is  $NH_2$  oder  $NO_2$ ,

and E, D,  $R^9$ , and q are as defined in claim 1, to obtain a compound of formula V



V,

- c) subjecting the compound of formula V to a reduction step, if  $FG^2$  is  $NO_2$ , to transfer the  $NO_2$  group into a  $NH_2$  group, and reacting the compound of formula V, wherein  $FG^1$  is  $NHR^6$  and  $FG^2$  is  $NH_2$ , with  $Hal_3C-C(=NH)OA$  to obtain a compound of formula I, wherein  $R^{10}$  is  $CHal_3$ ; or with  $HalCN$  to obtain a compound of formula I, wherein  $R^{10}$  is  $NH_2$ ;
- d) and optionally transferring the compound obtained from step c) into a compound of formula I, wherein  $R^{10}$  is other than  $CHal_3$  or  $NH_2$ ;
- e) and optionally isolating and/or treating the compound of formula I as obtained by said reaction, with an acid, to obtain the salt thereof.



30. Compound of formula IIIb,




5

wherein  $R^8$ ,  $p$ ,  $Ar^1$  and  $Y$  are as defined in claim 1.

31. Compound of formula IV,

10



15

wherein

$FG^1$  is  $NHR^6$ ,

$FG^2$  is  $NH_2$  oder  $NO_2$ ,

and  $E$ ,  $D$ ,  $R^9$ , and  $q$  are as defined in claim 1.

20

25

30